Development of nano medicine for anti-bladder cancer based on human immunology

2016 Fiscal Year Final Research Report

• Project/Area Number: 26713002
• Research Category: Grant-in-Aid for Young Scientists (A)
• Allocation Type: Partial Multi-year Fund
• Research Field: Physical pharmacy
• Research Institution: Hokkaido University
• Principal Investigator: NAKAMURA Takashi 北海道大学, 薬学研究科(研究院), 助教 (20604458)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 膀胱がん / BCG / ナノ粒子 / がん免疫療法 / ヒト免疫学

Outline of Final Research Achievements

The purpose of this study is to develop a nanoparticle system achieving live BCG mediated antitumor effects against bladder cancer. We successfully found that the modification of PEGylated lipid into nanoparticles efficiently inhibited the aggregation of nanoparticle in human urine. We also developed the novel nanoparticle for efficient siRNA delivery to immune cells. The internalization of BCG cell wall skeleton in bladder cancer cells is essential for induction of antitumor effect. Moreover, we found key cytokines associated with antitumor effect of BCG by analyses with microarray and qRT-PCR. We currently progress selection of BCG components and development of Nano-BCG.

Free Research Field

薬物送達学　腫瘍免疫学